Start with the constraint, not the spreadsheet
When I supported a national network spanning clinics across 50 states, the recurring lesson was that growth stalled for operational reasons long before it stalled for financial ones. Sites opened on time and then ran at half capacity because referral flow had not been secured. Acquired practices looked accretive on paper and then lost the two clinicians who carried the caseload.
So the first question in any healthcare expansion analysis is not "what is cheaper". It is: what is the binding constraint on growth in this market? If the constraint is a licence, a clinician pool or an existing referral base, buying buys you the constraint. If the constraint is a model that does not exist yet, buying just buys you somebody else's version of the problem.
Build vs buy, compared
| Factor | Build | Buy |
|---|---|---|
| Time to first revenue | 9–24 months. Entity setup, licensing, clinician recruitment and payer or commissioner contracting all sit before the first patient. | 0–6 months. Revenue exists on day one; the work shifts to retention and integration. |
| Capital profile | Lower upfront cost, longer cash burn. Spend is staged but the runway requirement is easy to underestimate. | Higher upfront consideration, shorter burn. Multiples, earn-outs and working capital dominate the model. |
| Regulatory load | Full registration from scratch — CQC in the UK; state licensure, credentialling and payer enrolment in the US, state by state. | Inherited permissions, inherited history. Diligence on past inspections, complaints and clinical governance matters more than the paperwork. |
| Operating model control | Complete. Pathways, workflows and technology are designed the way you want them from day one. | Constrained. You inherit habits, rotas, systems and a culture that may resist the model you intend to run. |
| Where it usually fails | Demand generation. Capacity gets built before referral flow is proven, and utilisation never reaches plan. | Integration. Clinician attrition, duplicated back office and an unrealistic synergy case erode the return. |
| Best when | The model is differentiated, the pathway is genuinely new, and there is patience for a slower ramp. | Speed, licences, clinician supply or an existing referral base are the binding constraint. |
UK into US: why build timelines compound
UK organisations consistently underestimate that the US is not one market. Licensure, credentialling and payer enrolment are handled state by state, and each additional state adds its own timeline rather than sharing the previous one. A build strategy that works well in two states can become unmanageable at ten without a repeatable market-entry playbook and a back office designed for multi-state operations.
That is why acquisition is often the faster route into the US — not for the revenue, but for the licences, the payer contracts and the clinicians already credentialled. The build decision then applies to the operating layer on top: pathways, technology and utilisation management.
US into UK: a single regime, concentrated demand
The UK reverses the problem. One regulator and one broad framework make building genuinely feasible, but demand sits with NHS commissioners, insurers and a small number of corporate buyers. Those relationships are earned over quarters, not weeks. Building capacity ahead of a contracted referral route is the most common and most expensive mistake I am called in to unpick.
The third option most leaders skip
Before committing capital either way, it is worth testing whether the capacity you need already exists inside the business. Reworking referral triage, booking and clinician utilisation frequently releases meaningful additional throughput without headcount or acquisition — and it makes both build and buy cases materially stronger, because the model you are about to replicate actually works.
Frequently asked questions
- Is building or buying cheaper for healthcare expansion?
- Building is usually cheaper in upfront consideration and more expensive in time and cash burn. Buying front-loads cost but shortens the path to revenue. Compare them on total cash required to reach a stable operating margin, not on headline price.
- What is different about entering the US versus the UK?
- The US is a fifty-market problem: licensure, credentialling and payer contracting are state by state, so build timelines compound with every state added. The UK is a single regulatory regime under CQC, but demand is concentrated in NHS and insurer relationships that take time to earn.
- What should diligence focus on when acquiring a provider?
- Clinician retention risk, real utilisation versus contracted capacity, referral concentration, clinical governance history, and how much of the reported margin depends on the founder personally.
Working through a build or buy decision?
A short call is usually enough to pressure-test the assumptions and identify which constraint is really driving the decision.
Book an Intro Call →